A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of BMS-833923 administered in combination with carboplatin and etoposide followed by BMS-833923 alone in subjects with extensive-stage Small Cell Lung Cancer (SCLC).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: Exelixis
• Treatments: Carboplatin; Etoposide; Etoposide phosphate

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed small cell lung cancer, without prior chemotherapy treatment

• Men and Women at least 18 years old

• Eastern Cooperative Oncology Group (ECOG) status 0-2

Exclusion Criteria:

• Significant cardiovascular disease

• Prior treatment of small cell lung cancer is not permitted, except for palliative radiation to a limited field excluding the chest (e.g. for painful metastasis).

• Symptomatic brain metastases

• Women pregnant or breastfeeding

• Women of childbearing potential (WOCBP) unwilling/unable to use acceptable method to avoid pregnancy

• Uncontrolled medical disorder or active infection

• Concurrent therapy with any other investigational product